Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2013 April;61(2) > Minerva Cardioangiologica 2013 April;61(2):125-34

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

  INTERVENTIONAL INNOVATION NOVEL THERAPIES AND THE BEST NEW DEVICE CONCEPT FOR 2013 

Minerva Cardioangiologica 2013 April;61(2):125-34

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

Left atrial appendage closure devices. Their role in 2013

Mangner N. 1, Sandri M. 1, Lurz P. 1, Dähnert I. 2, Schuler G. 1, Möbius-Winkler S. 3

1 Heart Center Department of Internal Medicine/Cardiology University of Leipzig, Leipzig, Germany; 2 Heart Center Department of Pediatric Cardiology University of Leipzig, Leipzig, Germany; 3 Asklepios Clinic Weissenfels Department of Cardiology, Weissenfels, Germany


PDF


Stroke prevention is the major goal in treating patients with atrial fibrillation. Warfarin therapy, if used appropriately, is highly effective in preventing thromboembolic events, but is simultaneously burdened by a narrow therapeutic window, multiple food and drug interactions, and a substantial bleeding risk. New pharmacological agents show only a modest reduction of bleeding complications compared to warfarin. Percutaneous device left atrial appendage (LAA) closure has now been technologically advanced as an additional and potential alternative to pharmacotherapy in patients with AF. Promising randomized data are obtainable with the WATCHMAN® device, while several other devices are in various stages of clinical and preclinical development. In this article we review the current knowledge and status of this technique.

top of page